IL1R1 and congenital rubella syndrome: Among clinically validated strategies for addressing CRS, IL-6R blockade with tocilizumab and IL-1R inhibition with anakinra have demonstrated robust mitigation of neurotoxicity and CRS in patients, marking a clear translational success [451].